Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Akers Biosciences delivers robust growth in third quarter

Monday, November 14, 2016 1:17
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Akers Biosciences PLC (LON:AKR, NASDAQ:AKER) is primed for a strong end to the year after delivering a robust showing in the third quarter.

Total revenues grew by 262% to US$613,198 in the three months to September 31, driven by sales of the company’s flagship PIFA Heparin-PF4 Rapid Assay.

The product is a breath test that is able determine quickly and efficiently whether a person has an allergy to a regularly prescribed blood thinner.

There are a couple of things note in the update. The first is the 341% rise in sales of the units, which raked in US$514,839.  The second is these sales came entirely from the US.

Why is that significant? Well, the company didn’t benefit at all from a Chinese order worth US$2.5mln.

The remaining US$2mln of the deal struck with Novotek for PIFA products is expected to go through in the final three months of the year.

Looking at the remainder of the results, Akers’ gross margin improved to 61%, meaning the company booked a gross profit of US$376,498. The company had cash in the bank of US$795,802.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.